March 9, 2020 / 11:13 AM / a month ago

BRIEF-Matinas Biopharma Reports Q4 Loss Per Share Of $0.04

March 9 (Reuters) - Matinas BioPharma Holdings Inc:

* MATINAS BIOPHARMA REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

* Q4 LOSS PER SHARE $0.04

* Q4 EARNINGS PER SHARE ESTIMATE $-0.03 — REFINITIV IBES DATA

* INITIATED ENHANCE-IT STUDY OF MAT9001 AGAINST VASCEPA. TOPLINE DATA EXPECTED Q4 2020

* INITIATED EFFICACY PHASE OF NIH-FUNDED ENACT STUDY OF MAT2203 IN CRYPTOCOCCAL MENINGITIS Q1 2020

* MATINAS BIOPHARMA HOLDINGS - BASED ON CURRENT PROJECTIONS, CO BELIEVES THAT CASH ON HAND IS SUFFICIENT TO FUND OPERATIONS INTO SECOND HALF OF 2022

* MATINAS BIOPHARMA - PLANS TO ANNOUNCE PROGRESSION FROM COHORT TO COHORT OVER COURSE OF 2020, BUT FULL DATA FROM MAT2203 ENACT WILL NOT BE AVAILABLE UNTIL SECOND HALF 2021 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below